Two unusual cases of Anderson-Fabry disease in a Japanese family.
A 16-year-old Japanese girl was admitted to our hospital on February 27, 2001, for acute renal failure. She had not shown proteinuria or hematuria in any school examination through 2000. The first renal biopsy specimen showed focal segmental glomerulosclerosis and tubulointerstitial change. Electron microscopy showed numerous myeloid bodies in the glomerular epithelium suggesting the diagnosis of Anderson-Fabry disease. After electron microscopy, we measured WBC alpha-galactosidase A, which was slightly decreased to 36.1 nmol/mg P/h (normal: 49.8 - 116.4). WBC alpha-galactosidase A levels for other family members were 74.3 for the mother, 4.8 for the father, 45.6 for the elder sister, and 16.3 for the younger sister. During the follow-up, she had two episodes of nephrotic syndrome, which responded well to steroid therapy. Both second and third renal biopsy showed numerous myeloid bodies by electron microscopy. A 52-year-old man, the father of the case one patient, was admitted for renal biopsy because of proteinuria and low levels of WBC alpha-galactosidase. Biopsy specimen showed typical changes under light microscopy and typical myeloid bodies by electron microscopy. Our cases underscore the importance of electron microscopy when examining the biopsy specimen and suggest that undiagnosed Anderson-Fabry disease may be present, in particular on chronic dialysis.
Chinen
S
S
Department of Investigative Medicine, Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus, Okinawa, Japan.
Tana
T
T
Kohagura
K
K
Yamazato
M
M
Iseki
K
K
Takishita
S
S
D000293:Adolescent; D001707:Biopsy, Needle; D000795:Fabry Disease / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D007150:Immunohistochemistry; D007564:Japan; D007677:Kidney Function Tests; D007678:Kidney Glomerulus / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010375:Pedigree; D011239:Prednisolone / Q000627:therapeutic use; D018570:Risk Assessment; D012720:Severity of Illness Index
D011239:Prednisolone